KEYNOTE-024的5年生存数据:帕博利珠单抗单药对比化疗一线治疗PD-L1 TPS≥50%转移性非小细胞肺癌
Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
KEYNOTE-024的5年生存数据:帕博利珠单抗单药对比化疗一线治疗PD-L1 TPS≥50%转移性非小细胞肺癌 |
| 评价者:陆舜 |
Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% |
| |